EP Patent

EP4619003A1 — Methods for treating poxvirus infections

Assigned to Gilead Sciences Inc · Expires 2025-09-24 · 1y expired

What this patent protects

The present disclosure relates to methods for treating poxvirus infections using a compound of Formula I: Formula I or a pharmaceutically acceptable salt or deuterated analog thereof.

USPTO Abstract

The present disclosure relates to methods for treating poxvirus infections using a compound of Formula I: Formula I or a pharmaceutically acceptable salt or deuterated analog thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP4619003A1
Jurisdiction
EP
Classification
—
Expires
2025-09-24
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.